联系客服QQ:86259698

300294 深市 博雅生物


首页 公告 博雅生物:公司2024年度财务决算报告

博雅生物:公司2024年度财务决算报告

公告日期:2025-03-19


            华润博雅生物制药集团股份有限公司

                  2024年度财务决算报告

  华润博雅生物制药集团股份有限公司(以下简称公司)2024年12月31日合并及母公司资产负债表,2024年度合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表,以及财务报表附注业经毕马威华振会计师事务所(特殊普通合伙)审计,并且被出具标准无保留意见的审计报告。

  现将公司(合并)2024年度财务决算的相关情况汇报如下:

    一、主要会计数据和财务指标

                                                                      单位:元

      项目            2024 年          2023 年        本年比上年增减        2022 年

营业收入(元)      1,734,904,402.71      2,651,979,506.66            -34.58%  2,758,701,315.10

归属于上市公司股东    396,991,588.69      237,465,593.87            67.18%    432,197,553.97
的净利润(元)
归属于上市公司股东

的扣除非经常性损益    301,566,307.78      143,075,746.77            110.77%    392,124,538.69
的净利润(元)

经营活动产生的现金    299,781,256.89      641,727,504.66            -53.29%    596,437,198.85
流量净额(元)

基本每股收益(元/股)            0.79                0.47            68.09%            0.86

稀释每股收益(元/股)            0.79                0.47            68.09%            0.86

加权平均净资产收益            5.36%              3.28%  增加 2.08 个百分点            6.18%


      项目            2024 年末        2023 年末      本年末比上年末增      2022 年末

                                                                减

资产总额(元)      8,401,144,768.99      7,828,900,301.89              7.31%  8,033,175,408.45

归属于上市公司股东  7,487,150,950.41      7,319,750,577.78              2.29%  7,185,634,486.84
的净资产(元)

    二、财务状况、经营成果、现金流量分析

  (一)财务状况分析

  资产、负债项目重大变动情况

                                                                      单位:元

              2024 年末                2024 年初        比重增

 项目                  占总资                  占总资    减          重大变动说明

            金额      产比例      金额      产比例

货币    1,299,851,770.61  15.47%  1,961,478,737.03  25.05%  -9.58%  主要系并购绿十字所致

资金
交易

性金                                                              主要系赎回理财产品所致

融资    2,199,127,063.15  26.18%  3,362,460,838.13  42.95%  -16.77%



应收                                                              主要系非高信用应收票据重
票据      4,933,656.10  0.06%              -  0.00%    0.06%  分类所致

应收                                                              主要系并购绿十字及回款下
账款    448,470,861.75  5.34%  209,836,815.66  2.68%    2.66%  降所致

预付                                                              主要系预付研发和营销合同
款项      13,623,534.65  0.16%    4,667,704.75  0.06%    0.10%  款项增加及并购绿十字所致

其他                                                              主要系收回转让复大医药、天
应收      39,809,915.00  0.47%  264,403,475.84  3.38%  -2.91%  安药业款项所致



存货    995,427,153.22  11.85%  556,940,121.40  7.11%    4.74%  主要系并购绿十字所致

其他                                                              主要系发出商品增值税下降
流动      1,131,298.76  0.01%    1,766,406.94  0.02%  -0.01%  所致

资产

固定                                                              主要系并购绿十字所致

资产    837,410,357.02  9.97%  634,234,017.87  8.10%    1.87%

在建                                                              主要系智能工厂投入增加所
工程    321,002,761.13  3.82%    39,936,463.03  0.51%    3.31%  致

使用                                                              主要系浆站租赁厂房及并购
权资      11,789,360.01  0.14%    2,448,954.70  0.03%    0.11%  绿十字所致



无形                                                              主要系并购绿十字所致

资产    773,275,862.44  9.20%  269,314,822.71  3.44%    5.76%

开发                                                              主要系并购绿十字及华润博
支出    108,443,041.47  1.29%    53,220,110.15  0.68%    0.61%  雅生物研发投入增加所致

商誉    727,996,027.69  8.67%    72,612,799.46  0.93%    7.74%  主要系并购绿十字所致

递延

所得                                                              主要系并购绿十字所致

税资      73,537,423.69  0.88%    47,343,876.52  0.60%    0.28%


其他

非流                                                              主要系购买大额存单增加所
动资    370,193,402.78  4.41%  146,181,971.81  1.87%    2.54%  致



应付                                                              主要系智能工厂建设及研发
票据    207,704,840.99  2.47%    49,744,528.62  0.64%    1.83%  投入等票据支付增加所致

应付                                                              主要系并购绿十字所致

账款    149,918,235.66  1.78%    76,605,435.31  0.98%    0.80%


预收                                                              主要系预收租金已确认收入
款项                -  0.00%      110,564.57  0.00%    0.00%  所致

合同                                                              主要系年初预收货款后续发
负债      4,076,548.97  0.05%    12,205,635.32  0.16%  -0.11%  货冲减预收所致

一年

内到                                                              主要系浆站租赁厂房一年内
期的                                                              到期租赁负债增加及并购绿
非流      5,333,163.12  0.06%      907,054.30  0.01%    0.05%

动负                                                              十字所致



其他                                                              主要系合同负债下降及预提
流动        668,267.70  0.01%    1,083,642.25  0.01%    0.00%  退货损失下降所致

负债

长期                                                              主要系欣和药业已偿还银行
借款                -  0.00%    22,145,000.00  0.28%  -0.28%  借款所致

租赁